GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Endocyte Inc (NAS:ECYT) » Definitions » Net Income From Continuing Operations

Endocyte (Endocyte) Net Income From Continuing Operations : $-41.34 Mil (TTM As of Sep. 2018)


View and export this data going back to 2011. Start your Free Trial

What is Endocyte Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Endocyte's net income from continuing operations for the three months ended in Sep. 2018 was $-12.61 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Sep. 2018 was $-41.34 Mil.

Endocyte Net Income From Continuing Operations Historical Data

The historical data trend for Endocyte's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Endocyte Net Income From Continuing Operations Chart

Endocyte Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Net Income From Continuing Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only -18.03 5.46 -41.27 -43.89 -55.06

Endocyte Quarterly Data
Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -23.27 -8.56 -8.60 -11.57 -12.61

Endocyte Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Sep. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-41.34 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Endocyte (Endocyte) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Endocyte Inc (NAS:ECYT) » Definitions » Net Income From Continuing Operations
Comparable Companies
SZSE:002603 XKRX:086900 SZSE:300294 DNLI INSM ZLAB AKCA ZGNX ICPT RGNX LGND OSTO:VITR APLS PTLA BOM:539268 LSE:GNS BOLD TSE:4565 XLRN EBS
Traded in Other Exchanges
N/A
Address
Website
http://www.endocyte.com
Endocyte Inc is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases using precision medicine. Precision medicine is a medical discipline seeking to treat diseased cells with minimal impact on healthy cells. The company uses its proprietary technology to create novel small-molecule drug conjugates and companion imaging agents. The company's therapeutic areas are non-small cell lung, breast, colorectal, kidney, endometrial, prostate, and ovarian cancers; solid tumors; polycystic kidney disease; and inflammation.
Executives
Patrick Machado director 201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94107
John C Aplin director ONE AMERICAN SQUARE STE 2850, INDIANAPOLIS IN 46282
David R. Mcavoy officer: General Counsel C/O ENDOCYTE, INC., 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Alison A. Armour officer: Chief Medical Officer C/O ENDOCYTE, INC., 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Dawn Svoronos director C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Marc D Kozin director
Michael T. Andriole officer: Chief Financial Officer C/O ENDOCYTE, INC., 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Lesley Russell director 41 MOORES RD., FRAZER PA 19355
Beth Taylor officer: VP Finance & Chief Acctg Off 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Michael A. Sherman director, officer: President and CEO 3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906
Fred A Middleton director 400 SOUTH EL CAMINO REAL STE 1200, SAN MATEO CA 94402-1708
Peter D Meldrum director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Ann Hanham director ONE EMBRACADERO CTR, STE 2700, SAN FRANCISCO CA 94111
Chandra D Lovejoy officer: VP of Regulatory Affairs C/O PRONAI THERAPEUTICS, INC. 2150 - 885 WEST GEORGIA ST VANCOUVER A1 V6C 3E8
David D. Meek officer: Chief Commercial Officer 3000 KENT AVENUE; SUITE A1-100, WEST LAFAYETTE IN 47906